GSK has filed a patent for immunogenic compositions containing RSV F protein ecto-domain polypeptides, along with methods for their preparation and engineered RSV F proteins. The invention aims to induce an immune response to RSV F. GlobalData’s report on GSK gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on GSK, Human telomerase RT biomarker was a key innovation area identified from patents. GSK's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Rsv f protein immunogenic compositions and methods
The patent application (Publication Number: US20240034773A1) discloses a respiratory syncytial virus (RSV)-F protein with specific characteristics. Claim 7 describes the RSV-F protein as comprising a first polypeptide with a F1 fragment and a second polypeptide with a F2 fragment. Importantly, the F2 fragment lacks a transmembrane domain and a cytoplasmic tail, while including a trimerizing sequence from bacteriophage T4 fibritin. Additionally, Claim 8 specifies that the RSV-F protein should not contain a p27 region. The patent also covers the RSV-F protein being of either the RSV A subgroup (Claim 11) or the RSV B subgroup (Claim 12).
Furthermore, the patent application includes claims related to nucleic acids encoding the RSV-F protein, vectors containing the nucleic acid, and host cells with the vector. Claim 16 outlines a method for producing the RSV-F protein by culturing the host cell and recovering the protein from the culture media. Additionally, the patent covers an immunogenic composition comprising the RSV-F protein (Claim 17), which may further include an adjuvant (Claim 18). These claims highlight the specific characteristics and methods related to the RSV-F protein, emphasizing its potential applications in the development of immunogenic compositions for respiratory syncytial virus.
To know more about GlobalData’s detailed insights on GSK, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
